Akcea falls on new thrombocytopenia disclosure for volanesorsen

Akcea Therapeutics Inc. (NASDAQ:AKCA) lost $5.78 (26%) to $16.80 on Tuesday after disclosing an additional case of grade 4 thrombocytopenia in an open-label extension of its volanesorsen

Read the full 270 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE